


Propranolol

Cat. No.:	HY-B0573B		
CAS No.:	525-66-6		
Molecular Formula:	C ₁₆ H ₂₁ NO ₂		
Molecular Weight:	259.34		
Target:	Adrenergic Receptor; Bacterial		
Pathway:	GPCR/G Protein; Neuronal Signaling; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (385.59 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.8559 mL	19.2797 mL	38.5594 mL
		5 mM	0.7712 mL	3.8559 mL	7.7119 mL
10 mM		0.3856 mL	1.9280 mL	3.8559 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with K _i values of 1.8 nM and 0.8 nM, respectively ^[1] . Propranolol inhibits [³ H]-DHA binding to rat brain membrane preparation with an IC ₅₀ of 12 nM ^[2] . Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy ^[3] .
IC₅₀ & Target	β adrenergic receptor

In Vitro

Propranolol (10^{-7} M- 10^{-3} M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10^{-5} M in HemSCs^[4].

?Propranolol (10^{-9} M- 10^{-3} M; 24 and 48 hours) significant decreases cell proliferation at 10^{-4} M propranolol after 24 hours and 10^{-9} M propranolol after 48 hours in HemSCs^[4].

?Propranolol (50 μ M-200 μ M) 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces HemSC apoptosis^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:	HemSC cells
Concentration:	10^{-7} M- 10^{-3} M
Incubation Time:	24 and 48 hours
Result:	Increased the total ERK1/2 levels in a dose-dependent manner.

Cell Proliferation Assay^[4]

Cell Line:	HemSC cells
Concentration:	10^{-9} M- 10^{-3} M
Incubation Time:	24 and 48 hours
Result:	Suppressed HemSC proliferation.

Apoptosis Analysis^[4]

Cell Line:	HemSC cells
Concentration:	50 μ M, 100 μ M, or 200 μ M
Incubation Time:	24 hours
Result:	Induced HemSC cell death occurred via an apoptotic pathway.

In Vivo

Propranolol (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A xenograft mouse model of IH (infantile hemangiomas) with HemSC cells ^[4]
Dosage:	40 mg/kg
Administration:	Orally administration; 40 mg/kg; daily
Result:	Improved vessel development in the IH mouse model that correlated with MAPK pathway activation.

CUSTOMER VALIDATION

- Cell Metab. 2024 Jan 17:S1550-4131(23)00477-1.
- Nat Commun. 2023 May 2;14(1):2523.

- Bone Res. 2024 Mar 21;12(1):18.
- Chemosphere. 2019 Jun;225:378-387.
- Sci Signal. 2020 Nov 24;13(659):eaax0273.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70(5):1575-84. Epub 2006 Aug 1
- [2]. Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69(4):669-73.
- [3]. Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.
- [4]. Munabi NC, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 2016 Jan;5(1):45-55.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA